Literature DB >> 2556284

Mu opiate receptors are selectively labelled by [3H]carfentanil in human and rat brain.

M Titeler1, R A Lyon, M J Kuhar, J F Frost, R F Dannals, S Leonhardt, A Bullock, L T Rydelek, D L Price, R G Struble.   

Abstract

[11C]Carfentanil is a potent opioid agonist currently in use as a specific PET (position emission tomography) scan radioligand for brain mu opioid receptors. In order to investigate the receptor interactions of carfentanil in detail [3H]carfentanil was used as a radioligand for labelling receptors in rat and human brain tissue homogenates. [3H]Carfentanil was found to bind saturably and with high affinity (KD = 0.08 +/- 0.01 nM) to membranes prepared from human cortical (Bmax = 42 +/- 3 fmol/mg) and thalamic (Bmax = 84 +/- 3 fmol/mg) tissues and rat cortex (Bmax = 82 +/- 4 fmol/mg) and diencephalon (Bmax = 105 +/- 5 fmol/mg). Association (1.23 +/- 0.19 X 10(10) Mol-1 X min-1 and dissociation rate (0.19 +/- 0.03 min-1) constants were determined in human cortical tissues; results from studies in rat cortical, and rat diencephalon tissue homogenates produced similar kinetic rate constants. Competition studies with a variety of drugs indicated that [3H]carfentanil interacts primarily with mu opioid receptors in the four tissues studied; the affinities of a series of non-radioactive opioid ligands were essentially identical in the four tissues (correlation coefficients = 0.88-0.93). Naloxone, morphine, DAGO [( D-Ala2-MePhe4-Gly-ol5]enkephalin), DADL [( D-Ala2-D-Leu5]enkephalin) and EKC (ehtylketazocine) potently displaced specific [3H]carfentanil binding with nM potency while the kappa agonist U-69593, the sigma agonists (+)-SKF 10047, (+)-3-PPP [3-hydroxyphenyl)-N-propylpiperidine) and haloperidol and PCP (phencyclidine) were less potent displacing agents. The higher affinities of DAGO and morphine versus DADL for the [3H]carfentanil binding sites indicates that delta opioid receptors are not being labelled.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556284     DOI: 10.1016/0014-2999(89)90582-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

1.  Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats.

Authors:  Marianne Skov-Skov Bergh; Inger Lise Bogen; Nancy Garibay; Michael H Baumann
Journal:  Neuropharmacology       Date:  2019-04-06       Impact factor: 5.250

2.  Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women.

Authors:  Yolanda R Smith; Christian S Stohler; Thomas E Nichols; Joshua A Bueller; Robert A Koeppe; Jon-Kar Zubieta
Journal:  J Neurosci       Date:  2006-05-24       Impact factor: 6.167

3.  Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects.

Authors:  Elise M Weerts; Gary S Wand; Hiroto Kuwabara; Cynthia A Munro; Robert F Dannals; John Hilton; J James Frost; Mary E McCaul
Journal:  Alcohol Clin Exp Res       Date:  2011-06-20       Impact factor: 3.455

4.  The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol-dependent subjects.

Authors:  Gary S Wand; Elise M Weerts; Hiroto Kuwabara; Dean F Wong; Xiaoqiang Xu; Mary E McCaul
Journal:  Addict Biol       Date:  2012-01-20       Impact factor: 4.280

5.  Differential response to IV carfentanil in chronic cocaine users and healthy controls.

Authors:  Carolynne P Minkowski; David Epstein; J James Frost; David A Gorelick
Journal:  Addict Biol       Date:  2010-11-04       Impact factor: 4.280

6.  Opioid Release after High-Intensity Interval Training in Healthy Human Subjects.

Authors:  Tiina Saanijoki; Lauri Tuominen; Jetro J Tuulari; Lauri Nummenmaa; Eveliina Arponen; Kari Kalliokoski; Jussi Hirvonen
Journal:  Neuropsychopharmacology       Date:  2017-07-19       Impact factor: 7.853

Review 7.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

Review 8.  Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Authors:  Mark K Greenwald; Sandra D Comer; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2014-08-19       Impact factor: 4.492

Review 9.  Tobacco/nicotine and endogenous brain opioids.

Authors:  Yue Xue; Edward F Domino
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-12-23       Impact factor: 5.067

10.  Preparation and biodistribution in mice of [11C]carfentanil: a radiopharmaceutical for studying brain mu-opioid receptors by positron emission tomography.

Authors:  H Saji; D Tsutsumi; Y Magata; Y Iida; J Konishi; A Yokoyama
Journal:  Ann Nucl Med       Date:  1992-02       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.